GSK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
GSK is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company shows strong financial growth, positive catalysts in its pipeline, and a bullish technical setup. Despite some neutral to cautious analyst ratings, the long-term growth potential and recent approvals make it a solid choice for a long-term portfolio.
The technical indicators are bullish. The MACD is positive and contracting, RSI is neutral at 73.229, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading above its pivot point of 56.105, with resistance levels at 59.663 and 61.862, indicating potential for further upside.
Regulatory acceptance of RSV vaccine Arexvy in China.
EU approval for Nucala as a treatment for COPD, expanding its market potential.
Strong financial performance in Q4 2025, with revenue up 10.24% YoY and net income up 59.51% YoY.
Some analysts maintain Neutral or Hold ratings, citing mid-term growth challenges and limited pipeline readouts.
Stock trend analysis suggests potential short-term downside (-0.51% in the next day, -4.41% in the next month).
In Q4 2025, GSK demonstrated robust financial growth with a 10.24% YoY increase in revenue, a 59.51% YoY increase in net income, and a 61.54% YoY increase in EPS. Gross margin also improved to 69.7%, up 1.12% YoY.
Analysts have mixed views on GSK. TD Cowen and BofA raised their price targets, citing strong business performance and pipeline potential. However, Barclays downgraded the stock to Underweight, citing limited pipeline readouts and challenges for the new CEO. The overall sentiment is cautious but acknowledges long-term potential.
